First-in-human cell transplant trials in Parkinson's disease: The need for an improved informed consent process

Parkinsonism and Related Disorders

Volumn 21, Issue 8, 2015, Pages 829-832

  de Melo Martín, Inmaculada ^a   Hellmers, Natalie ^a   Henchcliffe, Claire ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bioethics; Informed consent; Parkinson's disease; Stem cell; Transplantation

Indexed keywords

ATTENTION; CYST; DYSKINESIA; EMBRYONIC STEM CELL; HUMAN; INFLAMMATION; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; MEDICAL INFORMATION; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; PARKINSON DISEASE; PATIENT CARE; PATIENT DECISION MAKING; PHASE 1 CLINICAL TRIAL (TOPIC); PIGMENT EPITHELIUM; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SHORT SURVEY; STEM CELL TRANSPLANTATION; THERAPEUTIC MISCONCEPTION; CLINICAL TRIAL (TOPIC); ETHICS;

CLINICAL TRIALS AS TOPIC; HUMANS; INFORMED CONSENT; PARKINSON DISEASE; STEM CELL TRANSPLANTATION;

EID: 84937520936     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.05.011     Document Type: Short Survey

References (33)

1. Drouin-Ouellet J., Barker R.A. Stem cell therapies for Parkinson's disease: are trials just around the corner?. Regen. Med. 2014, 9:553-555.
2. Kriks S., Shim J.W., Piao J., Ganat Y.M., Wakeman D.R., Xie Z., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011, 480:547-551.
3. Remy P. Biotherapies for Parkinson disease. Rev. Neurol. Paris. 2014, 170:763-769.
4. Mathews D.J., Sugarman J., Bok H., Blass D.M., Coyle J.T., Duggan P., et al. Cell-based interventions for neurologic conditions: ethical challenges for early human trials. Neurology 2008, 71:288-293.
5. Barker R.A., de Beaufort I. Scientific and ethical issues related to stem cell research and interventions in neurodegenerative disorders of the brain. Prog. Neurobiol. 2013, 110:63-73.
6. Williams-Gray C.H., Foltynie T., Brayne C.E., Robbins T.W., Barker R.A. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007, 130:1787-1798.
7. Ravina B., Swearingen C., Elm J., Kamp C., Kieburtz K., Kim S.Y. Long term understanding of study information in research participants with Parkinson's disease. Park. Relat. Disord. 2010, 16:60-63.
8. Dymek M.P., Atchison P., Harrell L., Marson D.C. Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease. Neurology 2001, 56:17-24.
9. Martin R.C., Okonkwo O.C., Hill J., Griffith H.R., Triebel K., Bartolucci A., et al. Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia. Mov. Disord. 2008, 23:1867-1874.
10. Karlawish J., Cary M., Moelter S.T., Siderowf A., Sullo E., Xie S., Weintraub D. Cognitive impairment and PD patients' capacity to consent to research. Neurology 2013, 81:801-807.
11. Lamont S., Jeon Y.H., Chiarella M. Assessing patient capacity to consent to treatment: an integrative review of instruments and tools. J.Clin. Nurs. 2013, 22:2387-2403.
12. Sundberg M., Bogetofte H., Lawson T., Jansson J., Smith G., Astradsson A., et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 2013, 31:1548-1562.
13. Barker R.A., Barrett J., Mason S.L., Bjorklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol. 2013, 12:84-91.
14. Folkerth R.D., Durso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology 1996, 46:1219-1225.
15. Mamelak A.N., Eggerding F.A., Oh D.S., Wilson E., Davis R.L., Spitzer R., et al. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease. J.Neurosurg. 1998, 89:592-598.
16. Keene C.D., Chang R.C., Leverenz J.B., Kopyov O., Perlman S., Hevner R.F., et al. Apatient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol. 2009, 117:329-338.
17. Cicchetti F., Saporta S., Hauser R.A., Parent M., Saint-Pierre M., Sanberg P.R., et al. Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12483-12488.
18. Gross R.E., Watts R.L., Hauser R.A., Bakay R.A., Reichmann H., von Kummer R., et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2011, 10:509-519.
19. Stead M., Eadie D., Gordon D., Angus K. "Hello, hello - it's English I speak!": a qualitative exploration of patients' understanding of the science of clinical trials. J.Med. Ethics 2005, 31:664-669.
20. Sherlock A., Brownie S. Patients' recollection and understanding of informed consent: a literature review. ANZ J. Surg. 2014, 84:207-210.
21. Kimmelman J. The therapeutic misconception at 25: treatment, research, and confusion. Hastings Cent. Rep. 2007, 37:36-42.
22. Lidz C.W. The therapeutic misconception and our models of competency and informed consent. Behav. Sci. Law 2006, 24:535-546.
23. Finder S.G., Bliton M.J., Gill C.E., Davis T.L., Konrad P.E., Charles P.D. Potential subjects' responses to an ethics questionnaire in a phase I study of deep brain stimulation in early Parkinson's disease. J.Clin. Ethics 2012, 23:207-216.
24. Valadas A., Coelho M., Mestre T., Guedes L.C., Finisterra M., Noronha A., et al. What motivates Parkinson's disease patients to enter clinical trials?. Park. Rel Disord. 2011, 17:667-671.
25. Kim S.Y., Schrock L., Wilson R.M., Frank S.A., Holloway R.G., Kieburtz K., de Vries R.G. An approach to evaluating the therapeutic misconception. IRB 2009, 31:7-14.
26. King N.M., Henderson G.E., Churchill L.R., Davis A.M., Hull S.C., Nelson D.K., et al. Consent forms and the therapeutic misconception: the example of gene transfer research. IRB 2005, 27:1-8.
27. de Melo-Martin I., Ho A. Beyond informed consent: the therapeutic misconception and trust. J.Med. Ethics 2008, 34:202-205.
28. Henderson G.E., Easter M.M., Zimmer C., King N.M., Davis A.M., Rothschild B.B., et al. Therapeutic misconception in early phase gene transfer trials. Soc. Sci. Med. 2006, 62:239-253.
29. Jansen L.A. Two concepts of therapeutic optimism. J.Med. Ethics 2011, 37:563-566.
30. Teng E.J., Petersen N.J., Hartman C., Matthiesen E., Kallen M., Cook K.F., Ford M.E. Effects of depression and social support on comprehension and recall of informed consent information among Parkinson disease patients and their caregivers. Int. J. Psychiatry Med. 2012, 43:67-83.
31. Kim S.Y. The ethics of informed consent in Alzheimer disease research. Nat. Rev. Neurol. 2011, 7:410-414.
32. Flory J., Emanuel E. Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA 2004, 292:1593-1601.
33. Hoffner B., Bauer-Wu S., Hitchcock-Bryan S., Powell M., Wolanski A., Joffe S. "Entering a clinical trial: is it right for you?": a randomized study of the clinical trials video and its impact on the informed consent process. Cancer 2012, 118:1877-1883.